Welcome to our dedicated page for Bristol-Myers Squibb Co news (Ticker: BMY), a resource for investors and traders seeking the latest updates and insights on Bristol-Myers Squibb Co stock.
Bristol-Myers Squibb news coverage encompasses regulatory developments, clinical trial results, product launches, business transactions, and corporate initiatives. The company's activities across oncology, hematology, immunology, cardiovascular, and neuroscience generate frequent updates that impact stakeholders in the healthcare and investment communities.
Regulatory announcements represent significant news events for Bristol-Myers Squibb, including approvals of new medicines, expanded indications for existing products, and regulatory submissions in various markets. These milestones reflect the progression of the company's pipeline from clinical development through regulatory review to market authorization. Priority review designations, breakthrough therapy designations, and orphan drug designations also generate news coverage as indicators of regulatory progress.
Clinical trial data releases occur at medical conferences, in peer-reviewed publications, and through corporate announcements. Results from pivotal trials evaluating new medicines or expanded uses of approved products receive particular attention from the medical community and investors. The company's extensive clinical trial portfolio across multiple therapeutic areas produces a steady stream of data readouts that inform understanding of product profiles and market potential.
Business development activities including acquisitions, licensing agreements, research collaborations, and strategic partnerships shape Bristol-Myers Squibb's long-term direction. These transactions can bring new assets into the pipeline, provide access to novel technologies, or establish collaborations with academic institutions and biotechnology companies. Divestitures and portfolio prioritization decisions also generate news coverage.
Commercial performance updates occur through periodic financial reporting and corporate presentations. These updates provide insight into product uptake, market penetration, competitive dynamics, and the impact of healthcare policy changes on business results. Manufacturing capacity expansions, supply chain developments, and commercial launches in new geographic markets represent additional categories of business news.
Corporate initiatives related to sustainability, patient access, health equity, research funding, and community engagement reflect broader aspects of Bristol-Myers Squibb's operations beyond drug development and commercialization. Leadership changes, organizational restructuring, and strategic priority shifts also contribute to news flow.
Bristol Myers Squibb (NYSE: BMY) announced positive topline Phase 3 SCOUT-HCM results showing Camzyos (mavacamten) met the primary endpoint with a statistically significant reduction in Valsalva LVOT gradient at Week 28 versus placebo in adolescents (ages 12 to <18).
The 44‑patient trial also met multiple secondary endpoints, reported safety consistent with the adult profile with no new signals, and continues into active treatment and a long‑term extension (totaling up to 200 weeks).
Bristol Myers Squibb (NYSE: BMY) will present at J.P. Morgan’s 44th Annual Healthcare Conference on Monday, January 12, 2026. The company's presentation and a fireside chat will begin at 7:30 a.m. PST / 10:30 a.m. ET.
The event will be webcast live at http://investor.bms.com, with presentation materials available at the start of the webcast. A replay and archived edition will be available after the event.
Bristol Myers Squibb (NYSE: BMS) announced an agreement with the U.S. government to improve affordability and supply resilience for Eliquis (apixaban).
Key items: Eliquis will be provided free to the Medicaid program starting January 1, 2026; the company will donate more than seven tons of Eliquis active pharmaceutical ingredient (API) to the U.S. Strategic Active Ingredient Reserve at no cost; BMS will receive three years of tariff relief; and BMS will enable direct-to-patient discounted access (about 80% off list price) for several branded medicines. The agreement’s specific commercial terms remain confidential. BMS reaffirmed a prior commitment to invest $40 billion in the United States over five years and said it will expand domestic production to support onshoring.
Bristol Myers Squibb (NYSE: BMY) will report results for the fourth quarter of 2025 on Thursday, February 5, 2026. Company executives will review financial results on a conference call beginning at 8:00 a.m. ET, with a live webcast available to investors and the public at http://investor.bms.com. Presentation materials will be posted to the same site before the call.
A replay of the webcast will be available at http://investor.bms.com approximately three hours after the conference call concludes. Contact emails: media@bms.com and investor.relations@bms.com.
Bristol Myers Squibb (NYSE: BMY) announced on December 11, 2025 that the U.S. FDA has accepted and granted priority review to the supplemental BLA for Opdivo (nivolumab) plus AVD for previously untreated Stage III or IV classical Hodgkin lymphoma in adults and pediatric patients 12 years and older. The FDA assigned a PDUFA target action date of April 8, 2026. The filing is supported by the randomized Phase 3 SWOG S1826 (CA2098UT) study, which lists progression-free survival as the primary endpoint and overall survival among key secondary endpoints. The study is sponsored by the National Cancer Institute and co-sponsored and supplied by Bristol Myers Squibb.
Bristol Myers Squibb (NYSE: BMY) announced a quarterly common-stock dividend of $0.63 per share, payable on February 2, 2026 to holders of record as of January 2, 2026. This quarterly rate is a 1.6% increase from last year’s $0.62 rate and implies an annual dividend rate of $2.52 for fiscal 2026 (subject to the board’s quarterly review). The company also declared a quarterly dividend of $0.50 per share on its $2.00 convertible preferred stock, payable March 2, 2026 to holders of record as of February 3, 2026. This marks the 17th consecutive year the company has increased the dividend and the 94th consecutive year the company has paid a dividend.
Bristol Myers Squibb (NYSE: BMY) presented lymphoma data at ASH 2025 highlighting targeted protein degradation and cell therapy advances. Key readouts: golcadomide plus R-CHOP showed a 24-month PFS of 79% with CMR 88% and MRD negativity 90%; golcadomide plus rituximab in FL showed ORR 97% and CRR 78%; BMS-986458 monotherapy showed ORR 65% overall. Long-term Breyanzi results: four-year PFS 52.2% and OS 61.5% in TRANSFORM; TRANSCEND FL 36-month CR 94% and DOR 70%. No new safety signals reported for investigational agents; Breyanzi safety profile reaffirmed.
Bristol Myers Squibb (NYSE: BMY) announced FDA approval of Breyanzi (lisocabtagene maraleucel) on December 5, 2025, as the first and only CAR T therapy for adults with relapsed or refractory marginal zone lymphoma (MZL) after ≥2 prior systemic therapies.
Approval was based on TRANSCEND FL MZL cohort results: ORR 95.5% (n=66), CR 62.1%, median duration of response not reached, and 90.1% of responders in response at 24 months; safety was consistent with prior data.
Terray Therapeutics announced on December 3, 2025 that it achieved a discovery milestone in its multi-target collaboration with Bristol Myers Squibb (NYSE: BMY). The milestone used Terray’s EMMI platform, which integrates generative AI, high-throughput chemical experimentation, and a rapidly expanding 13B+ target-ligand binding database with an automated lab.
The company said EMMI enables rapid, iterative discovery and optimization of novel small molecules for difficult-to-drug targets by combining advanced hardware, AI models, and structure-activity data to accelerate identification of development candidates for areas with significant unmet medical need.
Bristol Myers Squibb (NYSE: BMS) announced on December 3, 2025 that the ADEPT-2 Phase 3 study in psychosis associated with Alzheimer’s disease will continue with additional patient enrollment after a blinded review identified site-level irregularities.
The company excluded data from the affected sites before database lock, ran an independent interim efficacy and safety analysis with FDA consultation, and the Data Monitoring Committee recommended resuming enrollment to the original target population. BMS remains blinded to study data and expects ADEPT program readouts, including ADEPT-2, by end of 2026.
FAQ
What is the current stock price of Bristol-Myers Squibb Co (BMY)?
What is the market cap of Bristol-Myers Squibb Co (BMY)?
